top of page
  • Writer's pictureANPDF

Intrabio Media Release | June 29, 2023

"IntraBio Announces Positive Pivotal Trial Results of IB1001 for the Treatment of Niemann-Pick Disease Type C"

Read the full article here:

IntraBio NPC Phase III Trial Results 3F28
Download PDF • 164KB

  • IB1001 showed a clinically meaningful improvement in symptoms, functioning, quality of life, and cognition in both pediatric and adult patients with NPC

  • IB1001 was safe and well-tolerated with a favorable safety profile consistent with previous clinical and pre-clinical studies

  • Based on these positive results, IntraBio plans to file for marketing authorization with IB1001 with the FDA and EMA


To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."

Ways to support NP-C in Australia:

47 views0 comments


Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page